Model Systems for Development of Pain Gene Therapy

$1,482,497P01FY2007DKNIH

University Of Pittsburgh At Pittsburgh, Pittsburgh PA

Investigators

Linked publications & trials

Paper 39284030 Paper 29950408 Paper 28702475 Paper 28473703 Paper 27614209 Paper 27441042 Paper 27382601 Paper 26204493 Paper 25775541 Paper 25553823 Paper 24807488 Paper 24671677 Paper 24369058 Paper 23609618 Paper 23316929 Paper 23174234 Paper 23152509 Paper 23131023 Paper 23070115 Paper 22951005 Paper 22820170 Paper 22668775 Paper 22593113 Paper 22565023 Paper 22439790 Paper 22402319 Paper 22341128 Paper 22089494 Paper 22052241 Paper 21796661 Paper 21741472 Paper 21614028 Paper 21599974 Paper 21596054 Paper 21486703 Paper 21081904 Paper 21068718 Paper 20924362 Paper 20924361 Paper 20861246 Paper 20676389 Paper 20663524 Paper 20662742 Paper 20609516 Paper 20463073 Paper 20377371 Paper 20132484 Paper 19818042 Paper 19618450 Paper 19357694 Paper 19357693 Paper 19293775 Paper 19279288 Paper 19242524 Paper 19225548 Paper 19129446 Paper 18990298 Paper 18973552 Paper 18958369 Paper 18922082 Paper 18841093 Paper 18787207 Paper 18761380 Paper 18668142 Paper 18579738 Paper 18567517 Paper 18554636 Paper 18495826 Paper 18463685 Paper 18403116 Paper 18358516 Paper 18337317 Paper 18336248 Paper 18321553 Paper 18206170 Paper 18034230 Paper 18033311 Paper 18006008 Paper 17876111 Paper 17676048 Paper 17157347 Paper 16989604 Paper 16779871 Paper 16735041 Paper 16729280 Paper 16704745 Paper 16673413 Paper 16541122 Paper 16507116 Paper 16352538 Paper 16288496 Paper 16242997 Paper 16240988 Paper 15879146 Paper 15771964 Paper 15448108 Paper 15373787 Paper 15312999 Paper 15308696 Paper 15006613

Abstract

[unreadable] In the previous period of funding we developed gene transfer vectors based on the herpes simplex virus[unreadable] (HSV) to deliver genes with high efficiency to peripheral sensory neurons. We have exploited this property[unreadable] to develop non-replicating HSV vectors that provide an analgesic effect in models of somatic pain[unreadable] (inflammatory pain, neuropathic pain, and pain resulting from cancer) and visceral pain (bladder[unreadable] inflammation). In this renewal we focus our efforts to further develop HSV vectors for treatment of acute and[unreadable] chronic pain related to diabetes and painful bladder syndromes. Project 1 will explore the use of HSV-mediated[unreadable] transfer of genes that produce inhibitory neurotransmitters (glutamic acid decaraboxylase and[unreadable] proenkephalin) and anti-inflammatory peptides (IL4 and TNFDSR) in models of painful diabetic neuropathy.[unreadable] Project 2 will explore the analgesic effect of these vectors in acute and chronic rodent models of bladder[unreadable] pain. Project 3 will use a vector-based functional genomics approach to identify and characterize novel[unreadable] cellular gene products that inhibit or negatively modulate the activity of the vanilloid receptor TRPV1.[unreadable] Projects 1 and 2 are designed to provide preclinical evidence for vectors that may be developed for novel[unreadable] treatments of human disease, while Project 3 will lead to the identification and evaluation of novel gene[unreadable] products that would then be tested in a similar fashion. Administration (Core A), Preclinical Vector Production[unreadable] (Core B) and Gene Transfer Assays and Imaging (Core C) cores directly support the activities of all three[unreadable] projects. We believe this to be a timely and highly innovative proposal which is likely to provide new[unreadable] approaches to treatment of chronic pain related to diabetes and inflammation.

View original record on NIH RePORTER →